virbagen omega
virbac s.a. - rekombinantni omega interferon mačjega izvora - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. pri mačkah, okuženih s fiv, je bila smrtnost nizka (5%) in na zdravljenje ni vplivala.
iressa
astrazeneca ab - gefitinib - karcinom, pljučni pljuč - antineoplastična sredstva - iressa je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim non-small-cell lung cancer z aktiviranjem mutacije od epidermalna-rast-faktor-receptor tirozin kinaza.
xermelo
serb sas - telotristat etiprat - carcinoid tumor; neuroendocrine tumors - drugi proizvodi prebavnega trakta in metabolizma - xermelo je indicirano za zdravljenje driska sindrom karcinoid v kombinaciji z somatostatina analogne (ssa) terapija pri odraslih, neustrezno nadzira prp terapijo.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinom, pljučni pljuč - antineoplastična sredstva - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - metabolizem aminokislin, vrojene napake - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
fingolimod pharmascience 0,5 mg trde kapsule
fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod
fingolimod pharmascience 0,5 mg trde kapsule
fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod
mikafungin sandoz 50 mg prašek za koncentrat za raztopino za infundiranje
mikafungin - prašek za koncentrat za raztopino za infundiranje - mikafungin 50 mg / 1 viala - mikafungin
inzolfi 0,5 mg trde kapsule
fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod
efigalo 0,5 mg trde kapsule
fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod